share_log

Pfizer | SC TO-C: Written communication relating to an issuer or third party tender offer

Pfizer | SC TO-C: Written communication relating to an issuer or third party tender offer

輝瑞 | SC TO-C:投標報價書面通信
美股sec公告 ·  07/30 17:22
Moomoo AI 已提取核心訊息
Pfizer Inc. has announced a proposed modification offer for certain eligible participants holding Five-Year Total Shareholder Return Units (TSRUs) and Performance Share Awards (PSAs) granted in 2022 and 2023. The modification aims to extend the terms of these awards by two years, effectively converting them into seven-year TSRUs. This initiative is designed to retain talent and align their interests with those of shareholders by providing value tied to Pfizer's stock performance. The offer is voluntary and requires action from participants who wish to accept it during the open window period from August 12 through September 12, 2024. Pfizer will file a Tender Offer Statement with the SEC, and the offer will be made only through the Modification Offer and related materials, which will be available on the Fidelity NetBenefits online portal, Pfizer's website, and the SEC's website. The company has communicated this proposal to the eligible participants and will hold information sessions on August 14, 2024, to discuss the program details.
Pfizer Inc. has announced a proposed modification offer for certain eligible participants holding Five-Year Total Shareholder Return Units (TSRUs) and Performance Share Awards (PSAs) granted in 2022 and 2023. The modification aims to extend the terms of these awards by two years, effectively converting them into seven-year TSRUs. This initiative is designed to retain talent and align their interests with those of shareholders by providing value tied to Pfizer's stock performance. The offer is voluntary and requires action from participants who wish to accept it during the open window period from August 12 through September 12, 2024. Pfizer will file a Tender Offer Statement with the SEC, and the offer will be made only through the Modification Offer and related materials, which will be available on the Fidelity NetBenefits online portal, Pfizer's website, and the SEC's website. The company has communicated this proposal to the eligible participants and will hold information sessions on August 14, 2024, to discuss the program details.
輝瑞公司已經宣佈,擬爲2022年和2023年授予的五年總股東回報單元(TSRUs)和業績股票獎勵(PSAs)的某些符合條件的參與者提出修改建議。修改旨在將這些獎項的期限延長兩年,有效轉換爲七年的TSRUs。此舉旨在通過提供與輝瑞股票表現相聯繫的價值,留住人才,並將他們的利益與股東的利益相一致。該提議是自願的,需要參與者在2024年8月12日至9月12日的開放時間內採取行動才能接受它。輝瑞將向美國證券交易委員會提交招標要約聲明,並僅通過修改建議和相關材料進行報價,這些材料將在富達NetBenefits在線門戶、輝瑞公司網站和美國證券交易委員會網站上提供。公司已向符合條件的參與者傳達了這一提議,並將於2024年8月14日舉行信息會議,討論計劃詳情。
輝瑞公司已經宣佈,擬爲2022年和2023年授予的五年總股東回報單元(TSRUs)和業績股票獎勵(PSAs)的某些符合條件的參與者提出修改建議。修改旨在將這些獎項的期限延長兩年,有效轉換爲七年的TSRUs。此舉旨在通過提供與輝瑞股票表現相聯繫的價值,留住人才,並將他們的利益與股東的利益相一致。該提議是自願的,需要參與者在2024年8月12日至9月12日的開放時間內採取行動才能接受它。輝瑞將向美國證券交易委員會提交招標要約聲明,並僅通過修改建議和相關材料進行報價,這些材料將在富達NetBenefits在線門戶、輝瑞公司網站和美國證券交易委員會網站上提供。公司已向符合條件的參與者傳達了這一提議,並將於2024年8月14日舉行信息會議,討論計劃詳情。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息